These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 22735362)

  • 21. Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats.
    Bykov IL; Palmen M; Rainsford KD; Lindros KO
    Inflammopharmacology; 2006 Mar; 14(1-2):36-41. PubMed ID: 16835711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
    Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
    Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence, risk factors and prognosis of acute kidney injury after transcatheter aortic valve implantation.
    Kong WY; Yong G; Irish A
    Nephrology (Carlton); 2012 Jul; 17(5):445-51. PubMed ID: 22390156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
    Kivitz A; Fairfax M; Sheldon EA; Xiang Q; Jones BA; Gammaitoni AR; Gould EM
    Clin Ther; 2008 Dec; 30(12):2366-77. PubMed ID: 19167595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
    Kivitz AJ; Espinoza LR; Sherrer YR; Liu-Dumaw M; West CR
    Semin Arthritis Rheum; 2007 Dec; 37(3):164-73. PubMed ID: 17570469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity.
    Suddek GM; El-Kenawi AE; Abdel-Aziz A; El-Kashef HA
    Chemotherapy; 2011; 57(4):321-6. PubMed ID: 21893983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.
    Kurnik D; Vesterman-Landes J; Bialik M; Katzir I; Lomnicky Y; Halkin H; Loebstein R
    Clin Ther; 2011 Apr; 33(4):456-64. PubMed ID: 21635991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication.
    Hung KH; Yang HB; Cheng HC; Wu JJ; Sheu BS
    J Gastroenterol Hepatol; 2010 Jan; 25(1):48-53. PubMed ID: 19793174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
    Knight S; Johns EJ
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):11-6. PubMed ID: 18047621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Celecoxib for the prevention of colorectal adenomatous polyps.
    Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
    N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
    Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
    Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.
    Cerchietti LC; Navigante AH; Castro MA
    Nutr Cancer; 2007; 59(1):14-20. PubMed ID: 17927497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
    Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E
    Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
    Sinsakul M; Sika M; Rodby R; Middleton J; Shyr Y; Chen H; Han E; Lehrich R; Clyne S; Schulman G; Harris R; Lewis J
    Am J Kidney Dis; 2007 Dec; 50(6):946-51. PubMed ID: 18037095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemopreventive effect of celecoxib in gastric cancer.
    Futagami S; Suzuki K; Hiratsuka T; Shindo T; Hamamoto T; Ueki N; Kusunoki M; Miyake K; Gudis K; Tsukui T; Sakamoto C
    Inflammopharmacology; 2007 Feb; 15(1):1-4. PubMed ID: 17323186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
    Rossat J; Maillard M; Nussberger J; Brunner HR; Burnier M
    Clin Pharmacol Ther; 1999 Jul; 66(1):76-84. PubMed ID: 10430112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
    Cheung R; Cheng TT; Dong Y; Lin HY; Lai K; Lau CS; Feng H; Parsons B
    Int J Rheum Dis; 2010 May; 13(2):151-7. PubMed ID: 20536600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib.
    Madan RA; Xia Q; Chang VT; Oriscello RG; Kasimis B
    Expert Opin Pharmacother; 2007 Jul; 8(10):1425-31. PubMed ID: 17661725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.